<ѻý>Gynecologic Oncology May Face a Future of Too Few Cases, Too Many Docsѻý> Subspecialists could see only one patient a week with a new cancer diagnosis, researcher says Mar 18, 2024
<ѻý>Raludotatug Deruxtecan Promising in Platinum-Resistant Advanced Ovarian Cancerѻý> Novel ADC targeting CDH6 achieves response in nearly 50% of patients Mar 17, 2024
<ѻý>Cancer Prevention Strategies Linked to Mortality Reduction in BRCA Carriersѻý> Cohort studies indicate oophorectomy, breast MRI surveillance save lives, researchers say Feb 29, 2024
<ѻý>Two-Stage Screening Strategy for Ovarian Cancer Continues to Show Progressѻý> Large study shows stage shift, high specificity, increasing PPV over 21 years Jan 24, 2024
<ѻý>Early Detection Is Key to Higher Cure Rates in Ovarian Cancerѻý> "We are not aware of precancer stages for ovarian cancer" Dec 13, 2023
<ѻý>Cancer Patient's Final Act: Destroying Medical Debtѻý> Viral campaign will erase some $60 million in medical debt Nov 22, 2023
<ѻý>Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancerѻý> Alone or combined with a PD-1 inhibitor, ubamatamab showed promise in phase I trial Nov 09, 2023
<ѻý>T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancersѻý> More responses, longer OS in subset with the highest levels of HER2 expression Nov 07, 2023
<ѻý>RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancerѻý> Impressive overall response rate with avutometinib-defactinib in RAMP 201 trial Nov 05, 2023
<ѻý>In BRCA Breast Cancer, Prophylactic Salpingo-Oophorectomy Tied to Better Survivalѻý> PSO should be performed early, particularly for those with the BRCA1 variant, researchers say Oct 04, 2023
<ѻý>Preoperative Algorithm Might Halve Unnecessary Oophorectomies in Childrenѻý> Researchers point to potential for reduction in lifelong consequences Oct 03, 2023
<ѻý>Is Being a Night Owl Unhealthy? CRC Screening Not Recommended Enoughѻý> Also in TTHealthWatch: CVD death and obesity Sep 16, 2023 podcast
<ѻý>How the Chemotherapy Shortage Is Affecting Frontline Cliniciansѻý> "How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert Sep 08, 2023 video
<ѻý>New Ovarian Cancer Drug Extends Survival in Resistant Diseaseѻý> "Practice changing" findings for tough-to-treat patient population Jun 04, 2023
<ѻý>Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancerѻý> Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib Jun 03, 2023
<ѻý>Many With Cancer Predisposition Diseases Unaware of Genetic Statusѻý> Moreover, a significant proportion do not qualify for genetic screening under current guidelines Apr 19, 2023
<ѻý>Risks Outweigh Benefits for BSO at Benign Hysterectomy in Younger Womenѻý> It's less clear-cut for postmenopausal women, study authors say Apr 18, 2023
<ѻý>VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapyѻý> Prospective study in heavily treated population is warranted, researcher says Mar 30, 2023
<ѻý>Novel Strategies Show Winning Potential in Ovarian Cancerѻý> High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib Mar 28, 2023
<ѻý>CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancerѻý> Responses in a fourth of patients, clinical benefit in up to 90% Mar 26, 2023
<ѻý>OS Benefit Eludes Second-Line Niraparib Maintenance in Ovarian Cancerѻý> Significant PFS results demonstrated in NORA trial don't extend to overall survival Dec 17, 2022
<ѻý>FDA OKs First Antibody-Drug Conjugate for Platinum-Resistant Ovarian Cancerѻý> Mirvetuximab soravtansine produced responses in almost a third of patients in pivotal trial Nov 15, 2022
<ѻý>Pandemic Led to Surgical Delays in Gynecologic Cancers, and Worse Outcomesѻý> One in five patients experienced changes in their care plan Oct 04, 2022
<ѻý>Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancerѻý> PARP inhibitor still has value as maintenance therapy, ARIEL3 investigator says Oct 01, 2022
<ѻý>'Potential Detrimental Effect' With Fourth-Line Olaparib in Ovarian Cancerѻý> Post-hoc data from SOLO3 show diverging results based on prior lines of therapy Sep 30, 2022
<ѻý>Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trialsѻý> Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib Sep 09, 2022
<ѻý>Does PARP Inhibitor Maintenance Induce Platinum Resistance in Ovarian Cancer?ѻý> Shorter progression-free interval with platinum chemotherapy after olaparib maintenance Sep 01, 2022
<ѻý>Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancerѻý> Lower all-cause, cancer-specific mortality in women who received the drugs around time of surgery Aug 29, 2022
<ѻý>Two Sides of Endosalpingiosis: Benign Growth or Harbinger of Cancer?ѻý> Concurrent malignancy more than twice as common as compared with endometriosis, study showed Aug 06, 2022
<ѻý>Prosthetic Mesh May Stand in the Way of Further Abdominal Operationsѻý> Prior incisional hernia repair associated with complications with later abdominal surgery Aug 04, 2022
<ѻý>Another Possible Use for Aspirin: Reducing Ovarian Cancer Riskѻý> Potential benefit seen in women with and without established cancer risk factors Jul 27, 2022
<ѻý>Drugmaker Pulls Third-Line PARP Inhibitor Approval in Ovarian Cancerѻý> Decision on rucaparib follows negative OS signal and "discussions" with FDA Jun 17, 2022
<ѻý>PARP Inhibitor Picks Up a Win in Frontline Maintenance for Ovarian Cancerѻý> Median PFS more than doubled with rucaparib after response to platinum-based chemotherapy Jun 07, 2022
<ѻý>IL-15 Agonist Impresses in Non-Muscle Invasive Bladder Cancerѻý> High response rate, 99%-100% cancer-specific survival at 2 years Jun 04, 2022
<ѻý>New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomyѻý> Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk Apr 05, 2022
<ѻý>Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancerѻý> Should the gynecologic oncology community reconsider IP therapy? Mar 22, 2022
<ѻý>Novel ADC Promising in Tough-to-Treat Ovarian Cancerѻý> Ocular AEs an issue with mirvetuximab in folate receptor alpha-high platinum-resistant disease Mar 20, 2022
<ѻý>Adjuvant Chemo Disappoints in Low-Grade Serous Ovarian Cancerѻý> Study suggests no improvement in overall survival Mar 19, 2022
<ѻý>Uterine Cancer Mortality Now Neck and Neck With Ovarian Cancerѻý> Advances in ovarian cancer, stagnation in uterine cancer, and "alarming" racial disparity Feb 09, 2022
<ѻý>A Better Option for Preserving Fertility in Gynecologic Cancer Patients?ѻý> In vitro maturation can result in both embryos and oocyte vitrification, researcher says Oct 19, 2021